Towards in vitro models for reducing or replacing the use of animals in drug testing
Nat Biomed Eng
.
2023 Dec 27.
doi: 10.1038/s41551-023-01154-7.
Online ahead of print.
Authors
David M Stresser
1
2
3
,
Anna K Kopec
4
5
6
,
Philip Hewitt
4
5
7
,
Rhiannon N Hardwick
4
5
8
,
Terry R Van Vleet
4
5
9
,
Prathap Kumar S Mahalingaiah
4
5
9
,
Denice O'Connell
4
10
11
,
Gary J Jenkins
12
4
13
,
Rhiannon David
4
5
14
,
Jessica Graham
4
15
16
17
,
Donna Lee
4
11
17
,
Jason Ekert
4
5
18
,
Aaron Fullerton
4
5
19
,
Remi Villenave
4
5
20
,
Piyush Bajaj
4
5
21
,
James R Gosset
4
5
22
,
Sherry L Ralston
4
11
23
,
Manti Guha
4
5
24
,
Alejandro Amador-Arjona
4
5
24
,
Kainat Khan
4
5
14
,
Saket Agarwal
4
5
25
,
Catrin Hasselgren
4
16
26
,
Xiaoting Wang
4
5
27
,
Khary Adams
4
11
28
,
Gaurav Kaushik
4
5
29
,
Arkadiusz Raczynski
4
5
30
,
Kimberly A Homan
31
32
33
Affiliations
1
Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, IL, USA. david.stresser@abbvie.com.
2
International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), . david.stresser@abbvie.com.
3
IQ Microphysiological Systems Affiliate (IQ-), . david.stresser@abbvie.com.
4
International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).
5
IQ Microphysiological Systems Affiliate (IQ-).
6
Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA.
7
Chemical and Preclinical Safety, Merck KGaA, Darmstadt, Germany.
8
Discovery Toxicology, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, San Diego, CA, USA.
9
Investigative Toxicology and Pathology, AbbVie, North Chicago, IL, USA.
10
Global Animal Welfare, AbbVie, North Chicago, IL, USA.
11
IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group.
12
Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, IL, USA.
13
IQ Translational and ADME Sciences Leadership Group (TALG).
14
Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK.
15
Product Quality & Occupational Toxicology, Genentech, Inc., South San Francisco, CA, USA.
16
IQ DruSafe.
17
Safety Assessment, Genentech, Inc., South San Francisco, CA, USA.
18
UCB Pharma, Cambridge, MA, USA.
19
Investigative Toxicology, Genentech, Inc., South San Francisco, CA, USA.
20
Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
21
Global Investigative Toxicology, Preclinical Safety, Sanofi, Cambridge, MA, USA.
22
Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc, Cambridge, MA, USA.
23
Preclinical Safety, AbbVie, North Chicago, IL, USA.
24
Discovery Biology, Incyte, Wilmington, DE, USA.
25
Investigative Toxicology, Early Development, Alnylam Pharmaceuticals, Cambridge, MA, USA.
26
Predictive Toxicology, Genentech, Inc., South San Francisco, CA, USA.
27
Translational Safety & Bioanalytical Sciences, Amgen Research, Amgen Inc., South San Francisco, CA, USA.
28
Laboratory Animal Resources, Incyte, Wilmington, DE, USA.
29
Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
30
Preclinical Safety Assessment, Vertex Pharmaceuticals, Inc, Boston, MA, USA.
31
International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), . homan.kimberly@gene.com.
32
IQ Microphysiological Systems Affiliate (IQ-), . homan.kimberly@gene.com.
33
Complex in vitro Systems Group, Genentech, Inc., South San Francisco, CA, USA. homan.kimberly@gene.com.
PMID:
38151640
DOI:
10.1038/s41551-023-01154-7
No abstract available